STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #546 by analyst upside · 2026-08-13
MOLN
Molecular Partners AG
Healthcare · Market Cap $155M · P/E 0x
ANALYST PRICE TARGET
+167.7%
implied upside to consensus target
Current Price $4.13
Consensus Target $11.06
Bull Target $16.86
Bear Target $3.73
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
1
Sell
0
52-Week Low $3.46
52-Week High $5.36
YTD Return -2.1%
FUNDAMENTALS
Market Cap $155M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.92
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.46
52-Week High $5.36
Current Price $4.13
Bear Target $3.73
Bull Target $16.86
● Now $4.13 ● Target $11.06
TRADING DATA
Avg Volume 6K
YTD Return -2.1%
Analyst Count 5
Consensus Buy
Upside to Target +167.7%
Last Updated 2026-08-13

ANALYST SUMMARY

Molecular Partners AG (MOLN) is currently trading at $4.13 with a Wall Street consensus price target of $11.06, implying potential upside of 167.7% over the next 12 months. 5 analysts currently cover MOLN, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.86, while the most cautious has a target of $3.73.

MOLN operates in the Healthcare sector with a market capitalisation of $155M. The stock is down 2.1% year-to-date and is currently trading near the lower end of its 52-week range of $3.46 – $5.36.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MOLN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-04-22 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-16 31% win rate (48 calls)
HC Wainwright & Co. ● Initiated
Buy 2026-01-27 31% win rate (48 calls)
JP Morgan - Reiterated
Neutral → Neutral 2025-12-08 43% win rate (7 calls)
JP Morgan - Reiterated
Neutral → Neutral 2025-09-03 43% win rate (7 calls)
LifeSci Capital ● Initiated
Outperform 2025-03-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
36
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →